权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Defining the biology of human cardiac stem/progenitor cells for their use as an allogeneic cell therapeutic agent for myocardial repair & regeneration

定义人类心脏干/祖细胞的生物学，使其用作心肌修复的同种异体细胞治疗剂

基本信息

批准号：
MR/P026508/1
负责人：
Georgina Ellison_Hughes
金额：
$ 24.96万
依托单位：
King's College London
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2017
资助国家：
英国
起止时间：
2017 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=MR%2FP026508%2F1
关键词：
Defining biology human cardiac stem

项目摘要

When someone suffers a heart attack some of their heart cells die and the heart is unable to heal itself and replace the cells that are lost; eventually the heart will fail. We and others have identified that the adult heart possesses stem cells, called cardiac stem cells, and my laboratory has shown that these stem cells have the unique potential to regenerate lost heart tissue following damage. The goal of my research is to design the best, most cost-effective and easy-to-apply protocols and interventions for treating patients by regenerating and repairing the heart tissue that has been lost. We have discovered substances secreted by the cardiac stem cells that stimulate their growth and ability to make new heart tissue. We have also discovered that stem cells derived from the heart have a unique ability to return to the damaged heart, if injected through the circulation. The aim of this project is to define the biology of cardiac stem cells derived from human myocardium. We will test their stability when propagated to large numbers of cells in culture. We will determine their ability to return to the damaged heart when injected through the circulation and we will determine the substances that the human cardiac stem cells secrete when they reach the heart. Finally, we will determine whether the human cardiac stem cells can stimulate repair and regeneration of the damaged heart, leading to improved heart function. It is envisioned that the results from this project will lead to the first in man clinical trial where human cardiac stem cells are injected into patients who have suffered a heart attack in an attempt to repair and regenerate heart cells and improve outcome.

当一个人遭受心脏病发作时，他们的一些心脏细胞会死亡，心脏无法自我愈合并取代失去的细胞;最终心脏会衰竭。我们和其他人已经确定，成人心脏拥有干细胞，称为心脏干细胞，我的实验室已经表明，这些干细胞具有再生受损心脏组织的独特潜力。我的研究目标是设计最好的，最具成本效益和易于应用的方案和干预措施，通过再生和修复已经失去的心脏组织来治疗患者。我们已经发现了心脏干细胞分泌的物质，这些物质可以刺激它们的生长和制造新心脏组织的能力。我们还发现，如果通过循环注射，来自心脏的干细胞具有返回受损心脏的独特能力。本项目的目的是明确从人类心肌中提取的心脏干细胞的生物学特性。我们将测试它们在培养中大量繁殖时的稳定性。我们将确定它们通过循环注射时返回受损心脏的能力，我们将确定人类心脏干细胞到达心脏时分泌的物质。最后，我们将确定人类心脏干细胞是否可以刺激受损心脏的修复和再生，从而改善心脏功能。据设想，该项目的结果将导致第一次人体临床试验，其中人类心脏干细胞被注射到心脏病发作的患者体内，试图修复和再生心脏细胞并改善结果。

项目成果

期刊论文数量（8）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Diabetes-Induced Cellular Senescence and Senescence-Associated Secretory Phenotype Impair Cardiac Regeneration and Function Independently of Age

DOI：
10.2337/db21-0536
发表时间：
2022-05-01
期刊：
DIABETES
影响因子：
7.7
作者：
Marino, Fabiola;Scalise, Mariangela;Cianflone, Eleonora
通讯作者：
Cianflone, Eleonora

Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms.

DOI：
10.1038/s41422-021-00573-y
发表时间：
2021-12
期刊：
Cell research
影响因子：
44.1
作者：
Zhu R;Yan T;Feng Y;Liu Y;Cao H;Peng G;Yang Y;Xu Z;Liu J;Hou W;Wang X;Li Z;Deng L;Wang S;Li J;Han Q;Li H;Shan G;Cao Y;An X;Yan J;Zhang Z;Li H;Qu X;Zhu J;Zhou S;Wang J;Zhang F;Gao J;Jin R;Xu D;Ma YQ;Huang T;Peng S;Zheng Z;Stambler I;Gilson E;Lim LW;Moskalev A;Cano A;Chakrabarti S;Ulfhake B;Su H;Xu H;Xu S;Wei F;Brown-Borg HM;Min KJ;Ellison-Hughes G;Caruso C;Jin K;Zhao RC
通讯作者：
Zhao RC

A protocol for extracting immunolabeled murine cardiomyocytes of high-quality RNA by laser capture microdissection.